Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
45 pending office actions • 3 clients • 40 examiners • 21 art units • 0 of 45 (0%) have an AI response strategy ready • 33 patents granted in the last 365 days
Taft Law has a career total of 7526 applications, with a focus on Biotechnology & Pharmaceuticals. The firm has a resolved allowance rate pct of 85.99. This percentage reflects the ratio of allowances to total resolved cases and characterizes the firm's historical performance across its 7526 career applications.
The firm averages 2.85 office actions per allowance, indicating the typical number of rejections or objections encountered before a grant. Currently, there are 35 pending office actions. This current workload is part of the firm's broader history and represents the active phase of prosecution for its clients in Biotechnology & Pharmaceuticals.
Based on the USPTO statutory response window for each pending office action. 19 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 19 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 17 (38%) |
| §103 only | 10 (22%) |
| §102 only | 1 (2%) |
| §112 only | 2 (4%) |
| Double-patenting + other | 1 (2%) |
| Multi-statute (no §101) | 13 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 3 | 70.0% | +31.6% |
| NGUYEN, BAO THUY L | 2 | 41.8% | +22.0% |
| MARCSISIN, ELLEN JEAN | 2 | 34.5% | +49.3% |
| NGUYEN, NAM P | 2 | 54.8% | +48.7% |
| BUTLER, SARAI E | 1 | 88.1% | +10.7% |
| SALEH, ZAID MUHAMMAD | 1 | 65.0% | +46.7% |
| PATEL, PRANAV N | 1 | 68.7% | +21.7% |
| WANG, JING | 1 | 100.0% | +0.0% |
| BORTOLI, JONATHAN | 1 | 76.3% | +41.2% |
| HUANG, WEN | 1 | 81.8% | +23.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18667208 | OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY | HUANG, WEN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | SINES, BRIAN J | 30d overdue |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | HRANEK, KAREN AMANDA | 25d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | COUNTS, GARY W | 8d overdue |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | VOLKOV, ALEXANDER ALEXANDROVIC | 4d overdue |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | JOHANSEN, PETER N. | 8d |
| 17931993 | CARRY-OVER MONITORING | HILL, GRACELYN MARKHAM | 13d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | MARCSISIN, ELLEN JEAN | 51d overdue |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | MARCSISIN, ELLEN JEAN | 19d overdue |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | NGUYEN, NAM P | 26d |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | NGUYEN, NAM P | 34d |
| 19288563 | METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM | BUTLER, SARAI E | — |
| 18935834 | METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER | SALEH, ZAID MUHAMMAD | — |
| 18810797 | METHOD FOR IMPROVING CROSS-FLOW FILTRATION AND CROSS-FLOW FILTRATION SYSTEM | PATEL, PRANAV N | — |
| 18668368 | METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM | BORTOLI, JONATHAN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| ROCHE DIAGNOSTICS OPERATIONS, INC. | 43 |
| Mochida Pharmaceutical | 1 |
| ROCHE SEQUENCING SOLUTIONS, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1678 | 4 |
| 1677 | 4 |
| 1657 | 3 |
| 1797 | 3 |
| 2881 | 2 |
| 1796 | 2 |
| 1758 | 2 |
| 1675 | 2 |
| 2872 | 1 |
| 3651 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19288563 | METHOD FOR DETECTING AND REPORTING AN OPERATION ERROR IN AN IN-VITRO DIAGNOSTIC SYSTEM AND AN IN-VITRO DIAGNOSTIC SYSTEM | Roche Diagnostics Operations, Inc. | BUTLER, SARAI E | §103§112Other | Non-Final OA | — | Pending | Aug 01, 2025 | |
| 18935834 | METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER | Roche Diagnostics Operations, Inc. | SALEH, ZAID MUHAMMAD | §103 | Non-Final OA | — | Pending | Nov 04, 2024 | |
| 18810797 | METHOD FOR IMPROVING CROSS-FLOW FILTRATION AND CROSS-FLOW FILTRATION SYSTEM | Roche Diagnostics Operations, Inc. | PATEL, PRANAV N | §103 | Non-Final OA | — | Pending | Aug 21, 2024 | |
| 18719252 | METHOD FOR CHARACTERIZATION OF A MASS SPECTROMETRY INSTRUMENT COMPRISING AT LEAST ONE MASS ANALYZING CELL | Roche Diagnostics Operations, Inc. | WANG, JING | 2881 | §101§103§112 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18668368 | METHOD AND SYSTEM FOR OPERATING A LABORATORY AUTOMATION SYSTEM | Roche Diagnostics Operations, Inc. | BORTOLI, JONATHAN | §101 | Non-Final OA | — | Pending | May 20, 2024 | |
| 18667208 | OPTICAL SYSTEM FOR FOURIER PTYCHOGRAPHY | Roche Diagnostics Operations, Inc. | HUANG, WEN | 2872 | §103 | Final Rejection | — | Pending | May 17, 2024 |
| 18649151 | TRANSPORT DEVICE AND LABORATORY SAMPLE DISTRIBUTION SYSTEM | Roche Diagnostics Operations, Inc. | JORGENSEN, ABBY A | 3651 | §103 | Non-Final OA | 3d overdue | Pending | Apr 29, 2024 |
| 18645358 | ON-BOARD CONJUGATION | Roche Diagnostics Operations, Inc. | NGUYEN, BAO THUY L | §102§103 | Non-Final OA | — | Pending | Apr 24, 2024 | |
| 18642895 | ADJUSTABLE ADAPTER AND LABORATORY SYSTEM | Roche Diagnostics Operations, Inc. | WHATLEY, BENJAMIN R | §102§103§112 | Non-Final OA | — | Pending | Apr 23, 2024 | |
| 18620273 | LIGHT SOURCE FOR GENERATING ILLUMINATION LIGHT | Roche Diagnostics Operations, Inc. | DOWNING, SAVANNAH STARR | 2884 | §103 | Final Rejection | 39d | Pending | Mar 28, 2024 |
| 18696730 | MR-PROADM MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | LEE, JAE W | 1759 | §101§103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
| 18692099 | CENTERING HOLDER FOR CENTERING ONE SAMPLE TUBE | Roche Diagnostics Operations, Inc. | WRIGHT, PATRICIA KATHRYN | §112 | Non-Final OA | — | Pending | Mar 14, 2024 | |
| 18433619 | CHIMERIC IGG-FC-BINDING LIGAND POLYPEPTIDE AND USES THEREOF FOR IGG AFFINITY PURIFICATION | Roche Diagnostics Operations, Inc. | SZPERKA, MICHAEL EDWARD | §103§112 | Non-Final OA | — | Pending | Feb 06, 2024 | |
| 18541476 | METHOD FOR IMMUNOSENSING ON A LIPID LAYER | Roche Diagnostics Operations, Inc. | DUNN, MCKENZIE A | §102§103DP | Non-Final OA | — | Pending | Dec 15, 2023 | |
| 18541624 | UNIVERSAL CALIBRATION FOR QUANTITATIVE MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | ALABI, OYELEYE A | §101§102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 | |
| 18566548 | AN ANALYZER SYSTEM | Roche Diagnostics Operations, Inc. | LI, LARRY | 2881 | §103 | Final Rejection | — | Pending | Dec 01, 2023 |
| 18561621 | sFRP4 AS BLOOD BIOMARKER FOR THE NON-INVASIVE DIAGNOSIS OF ADENOMYOSIS | Roche Diagnostics Operations, Inc. | COUNTS, GARY W | 1678 | §101§102§103§112 | Non-Final OA | 8d overdue | Pending | Nov 16, 2023 |
| 18558133 | IL6 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18558150 | ESM1 MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Roche Diagnostics Operations, Inc. | LANKFORD JR, LEON B | 1657 | §103 | Non-Final OA | — | Pending | Oct 30, 2023 |
| 18557890 | PRESEPSIN MARKER PANELS FOR EARLY DETECTION OF SEPSIS | Mochida Pharmaceutical Co., Ltd. | LANKFORD JR, LEON B | 1657 | §102§112 | Non-Final OA | — | Pending | Oct 27, 2023 |
| 18556849 | INFORMATION PROCESSING DEVICE FOR PROVIDING REFERENCE INFORMATION RELATING TO DIAGNOSIS OF THYROID DISEASE | Roche Diagnostics Operations, Inc. | HRANEK, KAREN AMANDA | 3684 | §101§103 | Final Rejection | 25d overdue | Pending | Oct 23, 2023 |
| 18352183 | PROGNOSTIC VALUE OF BIOMARKERS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HAVING STABLE DISEASE | Roche Diagnostics Operations, Inc. | SINES, BRIAN J | 1796 | §101§102§103§112 | Final Rejection | 30d overdue | Pending | Jul 13, 2023 |
| 18339760 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | Roche Diagnostics Operations, Inc. | WALLENHORST, MAUREEN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18337018 | LC-MS METHOD FOR DETECTING AND QUANTIFYING 11-OXYGENATED STEROIDS | Roche Diagnostics Operations, Inc. | SODERQUIST, ARLEN | 1797 | §102§103§112 | Final Rejection | 21d | Pending | Jun 18, 2023 |
| 18333347 | INTERFERENCE MONITORING FOR PROVIDING A VERIFIED ANALYTE MEASUREMENT | Roche Diagnostics Operations, Inc. | HYUN, PAUL SANG HWA | 1796 | §101§102§103§112 | Final Rejection | 33d | Pending | Jun 12, 2023 |
| 18309985 | TIMP1 AS A MARKER FOR CHOLANGIOCARCINOMA | Roche Diagnostics Operations, Inc. | DENT, ALANA HARRIS | 1643 | §102 | Final Rejection | 20d | Pending | May 01, 2023 |
| 18299750 | GRIPPING APPARATUS FOR GRIPPING SAMPLE CONTAINER | Roche Diagnostics Operations, Inc. | LEEDS, DANIEL JEREMY | 3731 | §102§103 | Final Rejection | — | Pending | Apr 13, 2023 |
| 18028235 | CIRCULATING TOTAL-NT-PROBNP (GLYCOSYLATED AND UNGLYCOSYLATED NT-PROBNP) AND ITS RATIO WITH NT-PROBNP (UNGLYCOSYLATED NT-PROBNP) IN THE ASSESSMENT OF ATRIAL FIBRILLATION | Roche Diagnostics Operations, Inc. | FRITCHMAN, REBECCA M | 1758 | §101§103 | Final Rejection | — | Pending | Mar 24, 2023 |
| 18021085 | IGFBP7 FOR THE ASSESSMENT OF SILENT BRAIN INFARCTS AND COGNITIVE DECLINE | Roche Diagnostics Operations, Inc. | WEIDNER, ADAM M | 1675 | §101§103§112 | Non-Final OA | — | Pending | Feb 13, 2023 |
| 18017073 | GDF-15 FOR PREDICTING THE DISEASE SEVERITY OF A PATIENT WITH COVID-19 | Roche Diagnostics Operations, Inc. | ZOU, NIANXIANG | 1671 | §101§103 | Final Rejection | 61d | Pending | Jan 19, 2023 |
| 18096477 | LC COLUMN HANDLING USING WEIGHTED COUNTERS | Roche Diagnostics Operations, Inc. | LEBRON, BENJAMIN L | 1773 | §101§102§103§112 | Final Rejection | — | Pending | Jan 12, 2023 |
| 17990903 | REAGENT FOR MASS SPECTROMETRY | Roche Diagnostics Operations, Inc. | ADAMS, MICHELLE | 1797 | §102§112 | Non-Final OA | — | Pending | Nov 21, 2022 |
| 17916251 | A METHOD OF ASSESSING A FEMALE'S RISK OF HAVING PCOS AS WELL AS PRODUCTS AND USES RELATING THERETO | Roche Diagnostics Operations, Inc. | VOLKOV, ALEXANDER ALEXANDROVIC | 1677 | §101§103§112 | Final Rejection | 4d overdue | Pending | Sep 30, 2022 |
| 17907039 | CORONA NUCLEOCAPSID ANTIGEN FOR USE IN ANTIBODY-IMMUNOASSAYS | Roche Diagnostics Operations, Inc. | JOHANSEN, PETER N. | 1644 | §103§112 | Final Rejection | 8d | Pending | Sep 22, 2022 |
| 17931993 | CARRY-OVER MONITORING | Roche Diagnostics Operations, Inc. | HILL, GRACELYN MARKHAM | 1685 | §101§103 | Non-Final OA | 13d | Pending | Sep 14, 2022 |
| 17891458 | IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 51d overdue | Pending | Aug 19, 2022 |
| 17814332 | SAMPLE INPUT INTERFACE | Roche Diagnostics Operations, Inc. | CHIU, MAY LEUNG | 1758 | §102§103§112 | Final Rejection | 54d | Pending | Jul 22, 2022 |
| 17838568 | PARTICLE-BASED IMMUNOASSAY USING A PEGYLATED ANALYTE-SPECIFIC BINDING AGENT | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103 | Final Rejection | 34d | Pending | Jun 13, 2022 |
| 17360121 | DETECTION OF BACTERIAL (MOLLICUTIES) CONTAMINATION | Roche Diagnostics Operations, Inc. | BERTAGNA, ANGELA MARIE | 1681 | §101§103§112 | Final Rejection | 14d | Pending | Jun 28, 2021 |
| 17350822 | METHODS FOR DETECTING AN ANALYTE USING STRUCTURE SWITCHING BINDING AGENTS | Roche Sequencing Solutions, Inc. | NGUYEN, BAO THUY L | 1677 | §102§103 | Final Rejection | — | Pending | Jun 17, 2021 |
| 17162140 | Use of Biomarkers in the Assessment of the Early Transition from Arterial Hypertension to Heart Failure | Roche Diagnostics Operations, Inc. | MARCSISIN, ELLEN JEAN | 1677 | §101§103§112 | Final Rejection | 19d overdue | Pending | Jan 29, 2021 |
| 17150504 | METHODS OF IDENTIFYING AN INDIVIDUAL AS HAVING OR BEING AT RISK OF DEVELOPING AN AMYLOID-POSITIVE DEMENTIA BASED ON MARKER MOLECULES AND RELATED USES | Roche Diagnostics Operations, Inc. | RAMADAN, OMAR | 1678 | §101§102§103§112 | Final Rejection | — | Pending | Jan 15, 2021 |
| 16825181 | MULTIVALENT MONO- OR BISPECIFIC RECOMBINANT ANTIBODIES FOR ANALYTIC PURPOSE | Roche Diagnostics Operations, Inc. | ESSEX, LAURA ANN | 1675 | §103 | Non-Final OA | — | Pending | Mar 20, 2020 |
| 16008281 | FKBP DOMAIN WITH TRANSGLUTAMINASE RECOGNITION SITE | Roche Diagnostics Operations, Inc. | DABKOWSKI, ERINNE R | 1654 | §112 | Final Rejection | 42d overdue | Pending | Jun 14, 2018 |
| 15892829 | ALKALINE PRETREATMENT OF PARVOVIRUSES FOR IMMUNOASSAYS | Roche Diagnostics Operations, Inc. | NGUYEN, NAM P | 1678 | §103§112 | Non-Final OA | 26d | Pending | Feb 09, 2018 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial